L-Dex Suggested as a New Standard of Care
Filed with ASX · · 2 pages · English
Earlier from ImpediMed
- PREVENT Trial Results Published - Outstanding Initial Data
- Appendix 4C - Quarter ended 30 June 2018
- Appendix 4C - Quarter ended 31 March 2018
- Interim Results of PREVENT Trial
- US FDA 510(k) Clearance for Bilateral Lymphoedema Assessment
Later from ImpediMed
- Response to ASX Aware Query
- S&P DJI Announces September 2018 Quarterly Rebalance
- ImpediMed Completes Asset Sale of XiTRON Technologies, Inc.
- Appendix 4C - Quarter ended 30 September 2018
- Ascension National Purchasing Agreement Received
Follow ImpediMed into a list and get an email when it puts out news.
Follow ImpediMed